共 50 条
- [41] A phase II neoadjuvant trial of sequential triweekly nanoparticle albumin-bound paclitaxel and cyclophosphamide followed by 5-fluorouracil/epirubicin/cyclophosphamide in the treatment of operable breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Masumoto, NorioKadoya, TakayukiAmioka, AiKajitani, KeikoEmi, AkikoShigematsu, HideoHaruta, RumiKataoka, TsuyoshiMatsuura, KazuoOkada, Morihito
- [42] A phase 2 study of de-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low risk pure HER2 breast cancerCANCER RESEARCH, 2020, 80 (04)Tanaka, SatoruMorishima, HirotakaOda, NaofumiMatsunami, NobukiTakashima, TsutomuNoda, SatoruKashiwagi, ShinichiroTauchi, YukieAsano, YukaKimura, KoseiFujioka, HiruyaTerasawa, RisaKawaguchi, KanakoIkari, AyanaMorimoto, TakashiMichishita, ShintaroKobayashi, ToshihiroSakane, JunnaNitta, ToshikatsuSato, NayukoHokimoto, NorihiroNishida, YukihiroIwamoto, Mitsuhiko
- [43] Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of responsePLOS ONE, 2019, 14 (02):Murphy, CaitlinMuscat, AndreaAshley, DavidMukaro, VioletWest, LindaLiao, YangChisanga, DavidShi, WeiCollins, IanBaron-Hay, SallyPatil, SujataLindeman, GeoffreyKhasraw, Mustafa
- [44] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancerCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338Yoshimoto, MasatakaTakao, ShintaroHirata, MasaruOkamoto, YasushiYamashita, SumioKawaguchi, YoshihiroTakami, MakotoFurusawa, HidemiMorita, SatoshiAbe, ChigusaSakamoto, Junichi
- [45] A PILOT NEOADJUVANT STUDY OF SEQUENTIAL NANOPARTICLE ALBUMIN-BOUND PACLITAXEL FOLLOWED BY FEC IN ADVANCED BREAST CANCERANNALS OF ONCOLOGY, 2012, 23 : 127 - 127Ohtani, S.Kochi, M.Abe, K.Sakata, Y.Hiraki, K.Fujiwara, Y.Iwamoto, Y.
- [46] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancerCancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338Masataka YoshimotoShintaro TakaoMasaru HirataYasushi OkamotoSumio YamashitaYoshihiro KawaguchiMakoto TakamiHidemi FurusawaSatoshi MoritaChigusa AbeJunichi Sakamoto
- [47] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of lifeDRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2189 - 2199Palumbo, RaffaellaSottotetti, FedericoTrifiro, GiuseppePiazza, ElenaFerzi, AntonellaGambaro, AnnaSpinapolice, Elena GiuliaPozzi, EmmaTagliaferri, BarbaraTeragni, CristinaBernardo, Antonio
- [48] Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: an interim safety analysisEJC SUPPLEMENTS, 2008, 6 (07): : 219 - 219Seidman, A. D.Conlin, A. K.Moynahan, M. E.Bach, A.Troso-Sandoval, T.Sugarman, S.Forero, A.Kerr, R.Wright, G.Hudis, C. A.
- [49] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Iwase, S.Yamamoto, D.Kitamura, K.Odagiri, H.Teramoto, S.Ohtani, S.Doi, T.Kinebuchi, K.Kuroda, Y.Nagumo, Y.
- [50] Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancerANNALS OF ONCOLOGY, 2020, 31 : S331 - S331Luo, T.Zhong, X.He, P.Yan, X.Tian, T.Wei, B.Zhang, Z.Li, J.Zheng, H.